| A 24-week, multicentre, non-interventional, prospective study to describe clinical outcomes of advancing therapy with iGlarLixi in patients with T2DM sub-optimally controlled on basal insulin with or without OADs in daily practice in Saudi Arabia |
Ongoing |
iGlarLixi |
4 |
OBS17984 |
King Fahad Medical City (Riyadh),King Fahad Specialist Hospital, Buraydah, Hira Hospital (Makkah) ,Al-AlSheikh Diabetes Cente (Riyadh) |
| PROSPECTIVE NON-INTERVENTIONAL MULTI-CENTER STUDY EVALUATING BLEEDING INCIDENCE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS AND NON-INHIBITORS TREATED WITH EMICIZUMAB AND OTHER HEMOPHILIA TREATMENTS IN A REAL-LIFE SETTING |
Ongoing |
emicizumab |
4 |
MO401001 |
King Abdulaziz Medical City NG (Jeddah) |
| A multi-national, multi-centre, prospective, single-arm, observational, non-interventional post-authorisation safety study to investigate long-term safety of Sogroya®(somapacitan) in adults with growth hormone deficiency (AGHD) under routine clinical practice |
Ongoing |
Sogroya® |
4 |
NN8640-451 |
My Clinic (Jeddah),King Fahad Medical City (Riyadh),Dr. Sulaiman Al-Habib Medical Group Olaya (Riyadh) |
| Low INR to Minimize bleeding with mechanical valves Trial (LIMIT) |
Ongoing |
WARFARIN SODIUM |
3 |
2231351 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized, Single Oral Dose, Open Label, Two Sequence, Two Treatment, Four Periods, Full Replicate Crossover Study to Determine the Bioequivalence of Azacitidine 300 mg Film Coated Tablets Versus Onureg® 300 mg Film Coated Tablets For Adult Patients with Acute Myeloid Leukaemia (AML) under Fasting Conditions |
Ongoing |
Azacitidine 300 mg Film- Coated Tablets |
BE |
HIK-AZA-2023-01 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam) |
| A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects with Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease |
Ongoing |
Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) |
3 |
VX21-CTX001-161 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight related complications or risk factors for CVD |
Ongoing |
BI 456906 |
3 |
1404-0040 |
King Faisal Specialist Hospital and Research Center (Riyadh) , King Fahad Specialist Hospital (Dammam), King Abdulaziz University Hospital (Jeddah),King Saud Medical City (Riyadh) |
| Open-label, long-term safety and efficacy study of Mim8 in participants with haemophilia A with or without inhibitors |
Ongoing |
NNC0365-3769 B (Mim8) |
3 |
NN7769-4532 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Prospective Observational study to describe the pattern and effectiveness of the utilization of different treatment options for Metastatic Renal Cell Carcinoma (OPERA) |
Ongoing |
Tyrosine Kinase inhibitors and Immunotherapy |
4 |
OPERA2020 |
King Faisal Specialist Hospital and Research Center (Jeddah) |
| A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy |
Ongoing |
Upadacitinib (Rinvoq) |
3 |
M23-698 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
